Synthorx is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Our proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. Our lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. We have additional cytokine Synthorin programs for the treatment of cancer and autoimmune disorders.
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesDecember 12, 2018
Synthorx to Present Preclinical Data for THOR-707, a “Not-Alpha” IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018November 9, 2018
More events are coming soon.